In 2022, the field of medicine and biology will still be favored by research institutions

According to recent data, from February 8 to February 14, about 99 listed companies in Shanghai and Shenzhen were investigated by the agency
.
Among them, a total of 24 companies were investigated by more than 20 institutions
.
In addition, there are 4 companies that have been surveyed by more than 200 institutions
.
It is worth noting that two of the four companies are pharmaceutical and biological companies
.
Huadong Medicine: Investigation of 243 Institutions On February 10, Huadong Medicine released a record form of investor relations activities, indicating that the company accepted 243 institutional research on February 9, 2022, and the types of institutions are QFII, insurance companies, others, and fund companies.
, overseas institutions, securities companies, sunshine private equity institutions
.
In fact, since Huadong Medicine officially launched the "Girl Needle" in China at the end of August 2021, its medical beauty business has been favored by many institutions.
As of January 19 this year, 379 institutions have gathered for research
.
Among them, on January 5, a total of 525 people from nearly 300 institutions and individual investors including Goldman Sachs Group, Gao Yi Assets, BlackRock and Sequoia Capital participated in the online meeting of Huadong Medicine
.
Then on the 10th, Huadong Medicine issued another announcement saying: Huatai-Pineapple, Toroa Management, Industrial Securities, Bank of Communications Schroders Fund, Ping An Asset, GF Fund, Nanhua Fund and other 40 institutions surveyed me on January 7, 2022 Division
.
The main contents of the investigation include key strategic layout directions, clinical results of some innovative drugs, and progress of liraglutide products
.
Mindray Medical: Survey of 202 Institutions Mindray Medical is a domestic medical device giant and solution provider.
The company's products cover three categories of life information and support, in vitro diagnosis and medical imaging systems
.
From February 8 to February 14, it has obtained a total of 202 institutional surveys
.
It is reported that since the beginning of this year, Mindray Medical has also been receiving intensive research from many institutions
.
430 institutions surveyed in one week last month
.
Specifically, according to the investor relations activity record sheet released by Mindray Medical on January 17, 2022, from January 4 to January 7, January 10 to January 14, and January 17, the company received a total of 742 participants from 430 institutions
.
In addition, it is worth mentioning that Mindray Medical is also a company favored by research institutions in 2021.
According to industry statistics, Mindray Medical will have a total of 3,040 surveys and 1,553 research institutions in 2021
.
Judging from the current development of Mindray Medical, the industry expects that in 2022, Mindray Medical will still be a company favored by research institutions
.
Conclusion On the whole, since the beginning of this year, institutional research has remained hot, especially in the field of medicine and biology
.
It is understood that in January, Mindray Medical, Jiu'an Medical, Puluo Pharmaceutical, Teyi Pharmaceutical, etc.
have received intensive research from more than 100 institutions
.
Following this trend, the industry generally believes that in 2022, the field of medicine and biology will still be favored by research institutions
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.